MedTrace Logo

The Neurobiological Effect of 5-HT2AR Modulation

NCT03289949 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-12-16

No results posted yet for this study

Summary

The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin). Magnetic resonance imaging (MRI) and positron emission tomography (PET) will be used as neuroimaging tools.

Conditions

  • Basic Science

Interventions

DRUG

Psilocybine

Oral dose of psilocybine.

DRUG

Ketanserin

Oral dose of ketanserin.

Sponsors & Collaborators

  • Gitte Moos Knudsen

    lead OTHER

Principal Investigators

  • Gitte M Knudsen, Professor · Neurobiology Research Unit, Rigshospitalet

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2030-06-01
Completion
2030-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03289949 on ClinicalTrials.gov